Regulatory Archives - Page 2 of 3

The Advancements of Gene Editing Technology for Safe and Effective Gene Therapy Products

The field of gene therapy has witnessed significant advancements with the development of genome editing technologies. These technologies allow scientists to break, modify, and edit specific genes in a DNA sequence-specific manner, opening up new possibilities for gene therapy. While traditional gene therapy involves the addition of new genes to human cells or tissue, genome […]

The Advancements of Gene Editing Technology for Safe and Effective Gene Therapy Products Read More »

Quality Assurance and Compliance

Insights, Pharmacovigilance, Regulatory / development

Ensuring that products and services meet the highest standards of quality and compliance is crucial, and Quality Assurance (QA) plays a pivotal role in achieving this. At DDReg Pharma Pvt Ltd, the QA department is an integral part of the organization’s success. The department focuses on delivering services that exceed customer expectations while adhering to

Quality Assurance and Compliance Read More »

Navigating Drug Manufacturing Inspections

Insights, Regulatory / development

The US FDA conducts drug manufacturing inspections for facilities to ensure they are compliant with the Current Good Manufacturing Practice (cGMP) standards. However, navigating through these inspections requires a clear and comprehensive understanding of several aspects. These include applicable manufacturing standards, site selection model, 483 forms, and how the FDA reviews the inspections and outcomes.

Navigating Drug Manufacturing Inspections Read More »

How does EMA use Artificial Intelligence and Large Language Models in Medicine Regulation?

Insights, Regulatory / development

Artificial Intelligence in Medicine Regulation– a perspective by Emer Cooke, Executive Director of the European Medicines Agency. Introduction Artificial Intelligence (AI) is revolutionizing the regulation of medicines by offering innovative solutions to enhance drug safety, efficacy, and overall patient well-being. With its ability to process vast amounts of data, identify patterns, and predict potential risks,

How does EMA use Artificial Intelligence and Large Language Models in Medicine Regulation? Read More »

Understanding the FDA’s Abbreviated New Animal Drug Application Pathway

Insights, Regulatory / development

The level of scrutiny surrounding animal medicinal products has strengthened more adverse events (AEs) associated with such products have emerged in animals. Indeed, AEs and adverse drug reactions (ADRs) is a cause of concern for veterinarians. Several cases of toxicity from commonly used drugs have been reported, in canines, for example. These include licosamides that

Understanding the FDA’s Abbreviated New Animal Drug Application Pathway Read More »

regulatory framework for cell, tissue, and gene therapy products

Convergence of regulatory frameworks surrounding cell, tissue, and gene therapy products

Insights, Regulatory / development

Cell, tissue, or gene therapy products (CTGTPs) can contain non-viable or viable human cells or tissues, viable animal cells or tissues, or recombinant nucleic acids and are intended for use in humans to treat, prevent, or even diagnosis conditions that are associated with high treatment burden [1]. However, regulations surrounding CTGTPs vary per region as

Convergence of regulatory frameworks surrounding cell, tissue, and gene therapy products Read More »

Impact of Russia Ukraine war on clinical Trails

The impact of the Russia-Ukraine war on clinical trials

Insights, Regulatory / development

The Russia-Ukraine war has undoubtedly affected millions of people in and around the world. Several industries have taken a huge hit where operational and business continuity has been threatened, the pharmaceutical industry being one of them. From the delays along the drug development pipeline, to non-compliance products in the market being at risk, the industry

The impact of the Russia-Ukraine war on clinical trials Read More »

DDReg’s RegTech space: your regulatory solution for achieving rapid market access

Insights, Regulatory / development

DDreg RegTech focuses on technologies that may facilitate the delivery of regulatory requirements more efficiently and effectively than existing capabilities. The global adoption of RegTech is a result of increased regulatory scrutiny, compliance costs, development of artificial intelligence, evolution of data science and increasing demands regarding cost-effective compliance solutions. With ever changing regulatory requirements, pharmaceutical

DDReg’s RegTech space: your regulatory solution for achieving rapid market access Read More »

Biologics development & regulatory approval – EMA perspective

Insights, Regulatory / development

Biologics development in Biologic medicinal products, particularly biosimilars, has revolutionized the treatment of chronic conditions. As biologic products lose patent protection, biosimilars emerge as more readily accessible treatment alternatives. In the European Union (EU), the European Medicines Agency (EMA) is responsible for product approval. The EMA was the first regulatory authority to establish a regulatory

Biologics development & regulatory approval – EMA perspective Read More »

Biosimilarity and Interchangeability in the MENA region

Insights, Regulatory / development

A biological drug (or Biosimilar) is one that is produced from a living organism or contains components of a living organism. They have become indispensable tools in modern medicine, for the treatment of life-threatening conditions. With an aging population and a growing demand for treating chronic conditions, biologic use is on the rise. However, they